Vilobelimab vilobelimab pemphigus vulgaris

Indicated For

pemphigus vulgaris

About This Medication

# GOHIBIC® (vilobelimab) Patient Guide: How to Get GOHIBIC at Low or No Cost GOHIBIC (vilobelimab) is an intravenous medication authorized under Emergency Use Authorization (EUA) by the FDA for treating certain hospitalized adults with severe COVID-19 who require invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).[1][4] While there is no traditional patient assistance program with income-based eligibility for outpatient use, InflaRx offers the **InflaRx Commitment Program** to broaden access by refunding treatment costs to eligible hospitals for patients who do not survive despite receiving the full course in line with EUA guidelines.[2] This guide explains eligibility, the drug, access options, and steps for patients and caregivers. ## About GOHIBIC (vilobelimab) **GOHIBIC** is a first-in-class monoclonal antibody targeting complement factor C5a, a part of the immune system involved in excessive inflammation during severe COVID-19.[2][4] It is **not FDA-approved** but available under EUA for hospitalized adults initiated within 48 hours of starting IMV or ECMO.[1][4][8] Clinical data showed treated patients had lower mortality risk at day 28 and 60 compared to placebo.[4] Treatment involves up to **six IV doses** on Days 1, 2, 4, 8, 15, and 22, as long as the patient remains hospitalized.[1] It is administered only in hospital settings by healthcare professionals, not for home use. Potential benefits include reduced death risk in critically ill COVID-19 patients, but risks exist—discuss with your doctor.[1] GOHIBIC addresses inflammation driving COVID-19 progression in the sickest patients on life support.[4] As of 2026, its EUA status continues amid evolving COVID-19 treatments.[1][4] ## Who Qualifies for GOHIBIC and Cost Support? **Patient eligibility** is clinical, not financial: Hospitalized adults with COVID-19 starting IMV or ECMO within 48 hours of GOHIBIC initiation.[1][2][4] Your doctor decides based on EUA criteria. **Cost support** via InflaRx Commitment Program targets **hospitals/institutions**, not patients directly. It refunds up to six doses to eligible facilities if the patient dies from COVID-19 in ICU after EUA-compliant treatment.[2] This encourages hospitals to stock GOHIBIC for time-critical use.[2] No patient-facing income eligibility exists in provided details—no thresholds for individuals, couples, or families.[ ] | Household Size | Income Threshold | FPL % | Notes | |---------------|------------------|-------|-------| | Individual | Not applicable | N/A | Clinical eligibility only; hospital-focused refund program.[2] | | Couple | Not applicable | N/A | No income-based PAP; inquire with hospital financial aid.[ ] | | Family of 3 | Not applicable | N/A | Commitment Program for non-surviving patients via institutions.[2] | | Family of 4 | Not applicable | N/A | General patient support hubs may assist with insurance (e.g., GoodRx mentions).[3] | Patients unable to afford care should ask hospitals about charity care, as GOHIBIC ordering is via specialty distributors.[2] ## Insurance Requirements No specific insurance mandates for GOHIBIC under EUA—it's for emergency hospital use.[1][4] Medicare, Medicaid, or private insurance may cover as part of inpatient COVID-19 treatment; coverage varies.[3] Uninsured patients: Hospitals can order via ASD Healthcare (1-800-746-6273 or service@asdhealthcare.com, NDC 83000-0110-04).[2] InflaRx Commitment Program aids facilities post-treatment if outcomes are poor.[2] **Insurance requirements**: None specified; consult hospital billing.[ ] ## Step-by-Step Application Process GOHIBIC is **hospital-administered**—no patient application like outpatient PAPs. 1. **Seek hospital care**: If critically ill with COVID-19 on IMV/ECMO, your provider assesses EUA eligibility.[1][4] 2. **Doctor initiates**: Within 48 hours of ventilation/ECMO, requests GOHIBIC ordering.[1][2] 3. **Hospital orders**: Via ASD Healthcare (phone: 1-800-746-6273, email: service@asdhealthcare.com).[2] 4. **Treatment starts**: Up to 6 doses IV in hospital.[1] 5. **Cost support**: If patient doesn't survive, hospital files Commitment Program claim via InflaRx site.[2] 6. **Financial aid**: Discuss hospital charity care or general support (e.g., GoodRx hubs).[3] No online patient portal or mailed apps—it's provider-driven.[2] ## Timeline and Delivery **Processing time**: Hospitals order directly; time-critical, so stock encouraged.[2] Delivery via ASD Healthcare—urgent for Day 1 dosing.[1][2] **Treatment timeline**: - Day 1: First dose within 48 hours of IMV/ECMO.[1] - Days 2,4,8,15,22: Additional doses if hospitalized.[1] **Delivery method**: IV infusion in ICU/hospital only—no home delivery.[1] Report side effects to FDA (1-800-FDA-1088) or InflaRx (pvusa@inflarx.de).[2] ## Alternatives if Denied or Ineligible - **Clinical denial**: Other EUA/approved COVID-19 therapies (e.g., antivirals, steroids) per doctor.[4] - **Cost issues**: Hospital financial assistance, state programs, or general pharma hubs.[3][5] No biosimilars listed.[ ] - **Non-COVID uses**: Vilobelimab in trials for other inflammation; not available.[7] - GoodRx for price checks/coupons if applicable.[3] ## Reauthorization Not outpatient, so no standard reauth. Hospitals reassess per EUA during hospitalization.[1] ## Disclaimer This guide is for informational purposes based on available data as of 2026. GOHIBIC is EUA-only, not FDA-approved.[1][8] Eligibility/coverage changes; consult healthcare provider, hospital billing, or InflaRx. Not medical/financial advice. Side effects possible—review Fact Sheet.[1] Word count: 942.

Program information last verified: March 29, 2026